Dimension Therapeutics Company Profile (NASDAQ:DMTX)

About Dimension Therapeutics

Dimension Therapeutics logoDimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DMTX
  • CUSIP:
Key Metrics:
  • Previous Close: $8.58
  • 50 Day Moving Average: $7.34
  • 200 Day Moving Average: $7.49
  • 52-Week Range: $5.39 - $15.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.64
  • P/E Growth: 0.00
  • Market Cap: $214.75M
  • Outstanding Shares: 25,029,000
Profitability:
  • Net Margins: -459.47%
  • Return on Equity: -66.58%
  • Return on Assets: -36.15%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 7.41%
  • Quick Ratio: 7.41%
Additional Links:
Companies Related to Dimension Therapeutics:

Analyst Ratings

Consensus Ratings for Dimension Therapeutics (NASDAQ:DMTX) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $18.57 (116.45% upside)

Analysts' Ratings History for Dimension Therapeutics (NASDAQ:DMTX)
Show:
DateFirmActionRatingPrice TargetDetails
9/12/2016Jefferies GroupSet Price TargetBuy$12.00View Rating Details
8/21/2016Chardan CapitalSet Price TargetHold$10.00View Rating Details
8/11/2016Canaccord GenuitySet Price TargetBuy$20.00View Rating Details
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
3/30/2016Goldman Sachs Group Inc.DowngradeBuy -> Neutral$10.00View Rating Details
3/29/2016Citigroup Inc.Lower Price TargetBuy$18.00 -> $15.00View Rating Details
12/3/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
11/6/2015Roth CapitalInitiated CoverageBuy$31.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Dimension Therapeutics (NASDAQ:DMTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/2/2016        
8/11/2016($0.43)($0.49)ViewN/AView Earnings Details
5/12/2016Q116($0.57)($0.38)$2.24 million$2.21 millionViewN/AView Earnings Details
3/24/2016($0.38)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dimension Therapeutics (NASDAQ:DMTX)
Current Year EPS Consensus Estimate: $-1.91 EPS
Next Year EPS Consensus Estimate: $-2.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.53)($0.53)($0.53)
Q4 20161($0.59)($0.59)($0.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dimension Therapeutics (NASDAQ:DMTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dimension Therapeutics (NASDAQ:DMTX)
Insider Ownership Percentage: 2.18%
Institutional Ownership Percentage: 85.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/7/2016K. Reed ClarkSVPSell5,000$10.00$50,000.00View SEC Filing  
10/27/2015Rishi GuptaDirectorBuy200,000$13.00$2,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dimension Therapeutics (NASDAQ:DMTX)
DateHeadline
publicnow.com logoDimension Therapeutics Announces Participation in Two Upcoming Investor Conferences (NASDAQ:DMTX)
www.publicnow.com - August 24 at 4:36 PM
capitalcube.com logoETF’s with exposure to Dimension Therapeutics, Inc. : August 24, 2016 (NASDAQ:DMTX)
www.capitalcube.com - August 24 at 4:36 PM
capitalcube.com logoDimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:DMTX)
www.capitalcube.com - August 15 at 4:49 PM
bizjournals.com logoMission Bay stalwart to lay off some researchers, trim focus (NASDAQ:DMTX)
www.bizjournals.com - August 11 at 10:29 PM
globenewswire.com logoDimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results (NASDAQ:DMTX)
globenewswire.com - August 11 at 8:47 AM
sg.finance.yahoo.com logoDimension Therapeutics reports 2Q loss (NASDAQ:DMTX)
sg.finance.yahoo.com - August 11 at 8:47 AM
finance.yahoo.com logoDimension Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:DMTX)
finance.yahoo.com - August 2 at 9:26 AM
bizjournals.com logoThis 'bold' IPO will say a lot about Wall Street, biotech and gene therapy (Video) (NASDAQ:DMTX)
www.bizjournals.com - July 20 at 9:35 AM
finance.yahoo.com logoAptuit LLC and Dimension Therapeutics Enter Strategic Partnership to Advance Select Dimension Programs Toward IND Filing (NASDAQ:DMTX)
finance.yahoo.com - July 7 at 8:00 AM
4-traders.com logoDimension Therapeutics : to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:DMTX)
www.4-traders.com - June 30 at 9:17 AM
publicnow.com logoDimension Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:DMTX)
www.publicnow.com - June 29 at 8:21 AM
News IconNew Broker Ratings For Argos Therapeutics Inc (ARGS) (NASDAQ:DMTX)
newsinfilm.com - June 24 at 4:46 PM
rttnews.com logoNYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race (NASDAQ:DMTX)
www.rttnews.com - June 23 at 8:28 AM
streetinsider.com logoDimension Therapeutics (DMTX) Announces Approval of Phase 1/2 Study Protocol for DTX301 (NASDAQ:DMTX)
www.streetinsider.com - June 22 at 9:20 AM
publicnow.com logoDimension Therapeutics Announces Recombinant DNA Advisory Committee’s Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency (NASDAQ:DMTX)
www.publicnow.com - June 22 at 8:09 AM
publicnow.com logoDimension Therapeutics Opens New Facility in Woburn and Expands Management Team (NASDAQ:DMTX)
www.publicnow.com - June 21 at 8:39 AM
finance.yahoo.com logoWill Dimension Therapeutics (DMTX) Continue to Surge Higher? (NASDAQ:DMTX)
finance.yahoo.com - June 14 at 8:13 AM
finance.yahoo.com logoIncreased Earnings Estimates Seen for Dimension Therapeutics (DMTX): Can It Move Higher? (NASDAQ:DMTX)
finance.yahoo.com - June 8 at 8:48 AM
finance.yahoo.com logoDimension Therapeutics (DMTX) Jumps: Stock Moves 6.7% Up (NASDAQ:DMTX)
finance.yahoo.com - June 8 at 8:06 AM
benzinga.com logoCantor Fitzgerald Initiates Dimension At Buy: 'Best In Class Therapies' (NASDAQ:DMTX)
www.benzinga.com - June 3 at 4:49 PM
capitalcube.com logoDimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:DMTX)
www.capitalcube.com - June 1 at 1:41 PM
fxpips.com logoStocks Gapping Up, May 24 – IDSA, STAF, MSON, DMTX, SSI, FMSA, REXI (NASDAQ:DMTX)
www.fxpips.com - May 24 at 11:12 AM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:DMTX)
biz.yahoo.com - May 20 at 4:34 PM
publicnow.com logoDimension Therapeutics Announces Presentations at the Upcoming 21st Congress of the European Hematology Association (EHA) (NASDAQ:DMTX)
www.publicnow.com - May 19 at 8:32 AM
forbes.com logoAnalysts See 11% Gains Ahead For IWV (NASDAQ:DMTX)
www.forbes.com - May 17 at 11:23 AM
sg.finance.yahoo.com logoDimension Therapeutics reports 1Q loss (NASDAQ:DMTX)
sg.finance.yahoo.com - May 12 at 11:53 AM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:DMTX)
biz.yahoo.com - May 12 at 9:02 AM
finance.yahoo.com logoDimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results (NASDAQ:DMTX)
finance.yahoo.com - May 12 at 9:00 AM
einnews.com logoIn Vivo Preclinical Studies Support a Promising Profile for Lead Candidate Currently in IND-Enabling Studies (NASDAQ:DMTX)
www.einnews.com - May 8 at 10:34 AM
publicnow.com logoDimension Therapeutics Announces Preclinical Data from Bayer-Partnered Hemophilia A Program at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting (NASDAQ:DMTX)
www.publicnow.com - May 7 at 12:07 PM
streetinsider.com logoDimension Therapeutics (DMTX) Announces Research Collaboration With PENN, Expansion of Inherited Metabolic Disease Portfolio (NASDAQ:DMTX)
www.streetinsider.com - May 6 at 11:22 AM
publicnow.com logoDimension Therapeutics Announces Gene Therapy Research Collaboration with the University of Pennsylvania and Expansion of Inherited Metabolic Disease Portfolio (NASDAQ:DMTX)
www.publicnow.com - May 5 at 2:31 PM
publicnow.com logoDimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial at American Society for Gene and Cell Therapy (ASGCT) Annual Meeting (NASDAQ:DMTX)
www.publicnow.com - May 5 at 8:21 AM
publicnow.com logoDimension Therapeutics Announces Participation in Two Upcoming Conferences (NASDAQ:DMTX)
www.publicnow.com - April 28 at 8:19 AM
News IconDimension Therapeutics Incorporated (NASDAQ:DMTX) Shorted Shares Increased By 4.44% (NASDAQ:DMTX)
www.bibeypost.com - April 21 at 10:50 AM
publicnow.com logoDimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting (NASDAQ:DMTX)
www.publicnow.com - April 18 at 8:21 AM
fxpips.com logoStock Gaps Up Morning Update – ABIL, GLDC, DMTX, CADC, WPRT, BAS, TCK, LEI, CHK, (NASDAQ:DMTX)
www.fxpips.com - April 13 at 10:49 AM
publicnow.com logoDimension Therapeutics to Present at the British Society for Gene and Cell Therapy (BSGCT) Annual Conference (NASDAQ:DMTX)
www.publicnow.com - April 6 at 8:20 AM
News IconChardan Capital Reiterates a Hold Rating on Dimension Therapeutics Inc (NASDAQ:DMTX)
lucenainformacion.com - April 1 at 10:26 AM
News IconAnalysts Downgrades Report: Dimension Therapeutics Inc (NASDAQ:DMTX)
solonews.net - April 1 at 10:26 AM
News IconDimension Therapeutics Cut to Neutral at Goldman Sachs (NASDAQ:DMTX) (NASDAQ:DMTX)
mediajuss.com - April 1 at 10:26 AM
bilbaoya.com logoDimension Therapeutics Inc (DMTX) Stock Rating Reaffirmed by Chardan Capital (NASDAQ:DMTX)
bilbaoya.com - April 1 at 10:26 AM
benzinga.com logoGoldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension (NASDAQ:DMTX)
www.benzinga.com - March 30 at 10:04 AM
finance.yahoo.com logoDIMENSION THERAPEUTICS, INC. Financials (NASDAQ:DMTX)
finance.yahoo.com - March 29 at 1:04 PM
thestreet.com logoPeek Under The Hood: IUSG Has 13% Upside (NASDAQ:DMTX)
www.thestreet.com - March 27 at 9:53 AM
bidnessetc.com logoDimension Therapeutics Inc Dips on Earnings Despite Top-Line Strength (NASDAQ:DMTX)
www.bidnessetc.com - March 25 at 10:10 AM
publicnow.com logoDimension Therapeutics Reports Recent Corporate Progress and Full Year 2015 Financial Results (NASDAQ:DMTX)
www.publicnow.com - March 24 at 9:33 AM
biz.yahoo.com logoDIMENSION THERAPEUTICS, INC. Files SEC form 10-K, Annual Report (NASDAQ:DMTX)
biz.yahoo.com - March 24 at 9:30 AM
streetinsider.com logoDimension Therapeutics' (DMTX) DTX301 Receives Positive EMA COMP Opinion as OTC Deficiency Treatment (NASDAQ:DMTX)
www.streetinsider.com - March 18 at 9:35 AM
finance.yahoo.com logo8:01 am Dimension Therapeutics announces that the EMA has issued a positive opinion recommending DTX301 for designation as an orphan medicinal product for the treatment of Ornithine Transcarbamylase Deficiency (NASDAQ:DMTX)
finance.yahoo.com - March 17 at 8:01 AM

Social

Dimension Therapeutics (NASDAQ:DMTX) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff